We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Lab-on-a-Chip Infection Test Provides Cheaper, Faster Portable Diagnostics

By LabMedica International staff writers
Posted on 15 Dec 2020
Rapid screening and low-cost diagnosis play a crucial role in choosing the correct course of intervention when dealing with highly infectious pathogens. More...
This is especially important if the disease-causing agent has no effective treatment.

Despite low-cost onsite testing for infectious diseases being the holy grail of nucleic acid (NA) diagnostics, there are still no inexpensive and handheld solutions in the market that can provide truly portable, rapid NA amplification and detection.

Bioengineers at the Imperial College London (London, UK) developed a disposable, ultra-low-cost integrated silicon-based point-of-need (PoN) tri-modal NA transducer, known as TriSilix, that can chemically amplify and electrochemically detect pathogen-specific sequences of NA quantitatively in real-time. The developed chip, is a 'micro laboratory' which performs a miniature version of the polymerase chain reaction (PCR) on the spot. PCR is the gold-standard test for detecting viruses and bacteria in biological samples such as bodily fluids, feces, or environmental samples.

TriSilix can be produced at wafer-scale in a standard laboratory and exploits the intrinsic properties of the semiconductor Si which can be used as a resistive heating device and thermistor simultaneously. The sample solution can be maintained at a single, specific temperature (needed for isothermal amplification of NA such as recombinase-polymerase amplification (RPA) or cycled between different temperatures (with a precision of ± 1.3 °C) for PCR while the exact concentration of amplicons is measured quantitatively and in real-time electrochemically. Each lab-on-a-chip contains a DNA sensor, temperature detector and heater to automate the testing process. A typical smartphone battery could power up to 35 tests on a single charge.

The team performed qPCR analysis of genomic DNA extracted from clinical samples of Mycobacterium avium subspecies paratuberculosis (MAP) K10 strain. The lowest experimentally detectable concentration was 20 fg at the 35th cycle which is equivalent to detection of a single MAP bacterium in the sample. The team also performed qPCR analysis of the complimentary DNA (cDNA) of SARS-CoV-2, the causative agent of COVID-19. Using TriSilix, they were able detect 1 pg of cDNA of SARS-CoV-2 quantitatively, in real-time with specificity against a cDNA sequence from a similar virus (SARS-CoV), in as low as 20 cycles of PCR (lasting ~40 min). After 35 cycles, the difference in the electroanalytical signal was five times, showing clear separation.

Estefania Nunez-Bajo, PhD, a Chemical Engineer and first author of the study, said: “Monitoring infections at home could even help patients, with the help of their doctor, to personalize and tailor their antibiotic use to help reduce the growing problem of antibiotic resistance.” The study was published on December 2, 2020 in the journal Nature Communications.

Related Links:
Imperial College London


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.